Thomas A. d‘Amato, MD, PhD, Rodney J

Slides:

Advertisements

Similar presentations

Size matters: A comparison of T1 and T2 peripheral non–small-cell lung cancers treated with stereotactic body radiation therapy (SBRT) Neal E. Dunlap,

Advertisements

Comparative Effectiveness of Adjunctive Bevacizumab for Advanced Lung Cancer: The Cancer Research Network Experience Debra P. Ritzwoller, PhD, Nikki.

Cost-Effectiveness of Pemetrexed Plus Cisplatin as First-Line Therapy for Advanced Nonsquamous Non-small Cell Lung Cancer Robert Klein, MS, Catherine.

Michael Y. Chang, MD, MPH, Steven J. Mentzer, MD, Yolonda L

Characteristics and outcomes of secondary nodules identified on initial computed tomography scan for patients undergoing resection for primary non–small.

Local recurrence after surgery for non–small cell lung cancer: A recursive partitioning analysis of multi-institutional data Chris R. Kelsey, MD, Kristin.

Effect of tumor size on prognosis in patients with non–small cell lung cancer: The role of segmentectomy as a type of lesser resection Morihito Okada,

Prognostic significance of histologic differentiation, carcinoembryonic antigen value, and lymphovascular invasion in stage I non–small cell lung cancer

Impact of tumor size on outcomes after anatomic lung resection for stage 1A non–small cell lung cancer based on the current staging system Shamus R.

Which patients should be operated on after induction chemotherapy for N2 non–small cell lung cancer? Analysis of a 7-year experience in 175 patients

Randomized Phase II Trial of Cisplatin, Etoposide, and Radiation Followed by Gemcitabine Alone or by Combined Gemcitabine and Docetaxel in Stage III A/B.

Outcomes of unexpected pathologic N1 and N2 disease after video-assisted thoracic surgery lobectomy for clinical stage I non–small cell lung cancer Hong.

Ground glass opacity of the lung: The veil that needs lifting

Outcomes after neoadjuvant or adjuvant chemotherapy for cT2-4N0-1 non–small cell lung cancer: A propensity-matched analysis Whitney S. Brandt, MD, Wanpu.

Centers for Disease Control “increased-risk” organ donor: Not so risky? Francis D. Pagani, MD, PhD The Journal of Thoracic and Cardiovascular Surgery

A Pharmacogenomic Study of Docetaxel and Gemcitabine for the Initial Treatment of Advanced Non-Small Cell Lung Cancer W Jeffrey Petty, MD, Sommer N.

John M. Varlotto, MD, Abram Recht, MD, John C. Flickinger, MD, Laura N

William M. DeCampli, MD, PhD

Phase II Trial of Paclitaxel and Cisplatin in Patients with Extensive Stage Small Cell Lung Cancer: Cancer and Leukemia Group B Trial 9430 Thomas E.

Patterns of survival and recurrence after surgical treatment of early stage non–small cell lung carcinoma in the ACOSOG Z0030 (ALLIANCE) trial Stacey.

Lobar and sublobar resection with and without brachytherapy for small stage IA non– small cell lung cancer Hiran C. Fernando, FRCS, FRCSEd, Ricardo S.

Interstitial tumor-associated macrophages combined with tumor-derived colony- stimulating factor-1 and interleukin-6, a novel prognostic biomarker in non–small.

Bigger The Journal of Thoracic and Cardiovascular Surgery

Meta-Analysis of First-Line Therapies in Advanced Non–Small-Cell Lung Cancer Harboring EGFR-Activating Mutations Benjamin Haaland, PhD, Pui San Tan,

Jeffrey Bradley, MD, Issam El Naqa, PhD Journal of Thoracic Oncology

The lord of the rings Antonio Miceli, MD, PhD

Effects of Chemotherapy on Survival of Elderly Patients with Small-Cell Lung Cancer: Analysis of the SEER-Medicare Database Laura C. Caprario, MD, MS,

Elizabeth A. David, MD, MAS, Stina W. Andersen, PhD, Laurel A

Treatment trends in early-stage lung cancer in the United States, 2004 to 2013: A time- trend analysis of the National Cancer Data Base Kathryn E. Engelhardt,

A systematic review and meta-analysis of stereotactic body radiation therapy versus surgery for patients with non–small cell lung cancer Christopher.

STAT3, Cten, and lung cancer: Simultaneous excitement and caution

Segmentectomy for selected cT1N0M0 non–small cell lung cancer: A prospective study at a single institute Hiroaki Nomori, PhD, Takeshi Mori, PhD, Koei.

Strategies to Improve Outcomes of Patients with EGFR-Mutant Non–Small Cell Lung Cancer: Review of the Literature Caicun Zhou, MD, PhD, Luan Di Yao, MD

Yang Zhang, MD, Haiquan Chen, MD, PhD

A Phase II Study of Paclitaxel + Etoposide + Cisplatin + Concurrent Radiation Therapy for Previously Untreated Limited Stage Small Cell Lung Cancer (E2596):

Aditya K. Kaza, MD The Journal of Thoracic and Cardiovascular Surgery

Impact of positive pleural lavage cytology on survival in patients having lung resection for non–small-cell lung cancer: An international individual patient.

Comparative Effectiveness of Adjunctive Bevacizumab for Advanced Lung Cancer: The Cancer Research Network Experience Debra P. Ritzwoller, PhD, Nikki.

Bevacizumab Maintenance in Patients with Advanced Non–Small-Cell Lung Cancer, Clinical Patterns, and Outcomes in the Eastern Cooperative Oncology Group.

Results of surgical intervention for p-stage IIIA (N2) non–small cell lung cancer: Acceptable prognosis predicted by complete resection in patients with.

A first start for lung transplantation?

Modest Reductions in Dose Intensity and Drug-Induced Neutropenia have No Major Impact on Survival of Patients with Non-small Cell Lung Cancer Treated.

Commentary: It's time to check our bias: Ensuring health equity for patients with lung cancer Pamela Samson, MD, MPHS The Journal of Thoracic and Cardiovascular.

A Phase 2 Randomized Trial of Paclitaxel and Carboplatin with or without Panitumumab for First-Line Treatment of Advanced Non–Small-Cell Lung Cancer

Induction chemoradiotherapy (carboplatin-taxane and concurrent 50-Gy radiation) for bulky cN2, N3 non–small cell lung cancer Hiroyasu Yokomise, MD, Masashi.

Jeevanantham Rajeswaran, PhD, Eugene H. Blackstone, MD

Fenton H. McCarthy, MD, MS, Nimesh D. Desai, MD, PhD

Prevalence of in vitro chemotherapeutic drug resistance in primary malignant pleural mesothelioma: Result in a cohort of 203 resection specimens Aneil.

Maintenance Therapy and Advanced Non–Small-Cell Lung Cancer: A Skeptic's View Martin J. Edelman, MD, Thierry Le Chevalier, MD, Jean-Charles Soria, MD,

Video-assisted resection for lung cancer results in fewer complications Lunxu Liu, PhD, MD, FRCS The Journal of Thoracic and Cardiovascular Surgery

Adjuvant Chemotherapy for Non-small Cell Lung Cancer: Practice Patterns and Outcomes in the General Population of Ontario, Canada Christopher M. Booth,

Passing the torch The Journal of Thoracic and Cardiovascular Surgery

Thomas A. d’Amato, MD, PhD, Rodney J. Landreneau, MD, Robert J

Development of a patient-centered aggregate score to predict survival after lung resection for non–small cell lung cancer Alessandro Brunelli, MD, Michele.

The Journal of Thoracic and Cardiovascular Surgery

Discussion The Journal of Thoracic and Cardiovascular Surgery

The future of cardiac surgery training: A survival guide

Sequence-dependent enhancement of paclitaxel toxicity in non–small cell lung cancer by 17-allylamino 17-demethoxygeldanamycin Dao M. Nguyen, MD, FRCSC,

Robert J. Cerfolio, MD, FACS, FCCP, Ayesha S. Bryant, MSPH, MD

Size matters: A comparison of T1 and T2 peripheral non–small-cell lung cancers treated with stereotactic body radiation therapy (SBRT) Neal E. Dunlap,

Comparison of surgical techniques for early-stage thymoma: Feasibility of minimally invasive thymectomy and comparison with open resection Arjun Pennathur,

Aritoshi Hattori, MD, Kenji Suzuki, MD

Matthew J. Schuchert, MD, Brian L

Who should decide margin length in pulmonary excision of lung cancer?

Kaplan–Meier curve for progression-free survival for gefitinib versus doublet chemotherapy in three phase III trials in first-line nonsmall cell lung cancer.

Samuel Kim, MD The Journal of Thoracic and Cardiovascular Surgery

A Randomized Phase II Trial Assessing in Advanced Non-small Cell Lung Cancer Patients with Stable Disease after Two Courses of Cisplatin-Gemcitabine an.

Journal changes and initiatives

Reappraise the advanced technique for tumor localization and sentinel lymph node assessment in clinical early-stage non–small cell lung cancer Chengwu.

Kristin A. Higgins, MD, Junzo P. Chino, MD, Neal Ready, MD, Mark W

Presentation transcript:

Chemotherapy resistance and oncogene expression in non–small cell lung cancer Thomas A. d‘Amato, MD, PhD, Rodney J. Landreneau, MD, William Ricketts, PhD, Weidong Huang, MD, PhD, Ricardo Parker, PhD, Eugene Mechetner, MD, Ing-Ru Yu, MS, James D. Luketich, MD The Journal of Thoracic and Cardiovascular Surgery Volume 133, Issue 2, Pages 352-363 (February 2007) DOI: 10.1016/j.jtcvs.2006.10.019 Copyright © 2007 The American Association for Thoracic Surgery Terms and Conditions

Figure 1 The frequency of chemotherapy resistance for NSCLC tumor cultures exposed to cisplatin (CPLAT), carboplatin (CARBP), etoposide (VP16), paclitaxel (TAXOL), vinorelbine (NAVBL), docetaxel (TAXTR), and gemcitabine (GEMCB) are shown as percentages. Low drug resistance (LDR) is inhibition of growth 1 SD above the population median; intermediate drug resistance (IDR) is inhibition between the population median and 1 SD below the median; and extreme drug resistant (EDR) tumors are 1 SD below the median population. The Journal of Thoracic and Cardiovascular Surgery 2007 133, 352-363DOI: (10.1016/j.jtcvs.2006.10.019) Copyright © 2007 The American Association for Thoracic Surgery Terms and Conditions

Figure 2 Correlation and concurrent chemotherapy resistance illustrating congruent patterns for NSCLC tumor cultures exposed in separate assays to like agents, cisplatin (CPLAT) and carboplatin (CARBO) (N = 1099, R = 0.76) (A) or to vinblastine (VIN) and vincristine (VCR) (N = 28, R = 0.92) (B), are shown as percent colony inhibition (PCI) for each drug tested. Each data point (jittered for clarity) represents the combined in vitro response for a single tumor culture. The Journal of Thoracic and Cardiovascular Surgery 2007 133, 352-363DOI: (10.1016/j.jtcvs.2006.10.019) Copyright © 2007 The American Association for Thoracic Surgery Terms and Conditions

Figure 3 Concurrent chemotherapy resistance patterns for NSCLC tumor cultures exposed in separate assays to one of four standard platinum-based chemotherapy doublets. A, Carboplatin (CARBO) and paclitaxel (TAXOL) (N = 1523, R = 0.189); B, cisplatin (CPLAT) and navelbine (NAVBL) (N = 1314, R = 0.018); C, cisplatin (CPLAT) and gemcitabine (GMCB) (N = 741, R = 0.182); and D, cisplatin (CPLAT) and docetaxel (TAXOT) (N = 994, R = 0.09) are shown for each pair as percent colony inhibition (PCI) for each drug tested. Each data point (jittered for clarity) represents the combined in vitro response for a single tumor culture. The Journal of Thoracic and Cardiovascular Surgery 2007 133, 352-363DOI: (10.1016/j.jtcvs.2006.10.019) Copyright © 2007 The American Association for Thoracic Surgery Terms and Conditions

Figure 4 Kaplan–Meier estimates of overall survival (A) and the time to progression of disease (B) in the ECOG study patients enrolled according to their assigned treatment (From Schiller JH, Harrington D, Belani CP, Langer C, Sandler A, Krook J, et al. Comparison of four chemotherapy regimens for advanced non–small-cell lung cancer. N Engl J Med. 2002;346:92-8. Reprinted by permission of the Massachusetts Medical Society. Copyright 2002 Massachusetts Medical Society. All rights reserved). The Journal of Thoracic and Cardiovascular Surgery 2007 133, 352-363DOI: (10.1016/j.jtcvs.2006.10.019) Copyright © 2007 The American Association for Thoracic Surgery Terms and Conditions